Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 29, 2020 16:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Host a Webinar on its Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook on Thursday, November 19, 2020

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
October 22, 2020 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Webcast Conference Call of Third Quarter 2020 Financial Results on November 5, 2020

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...
October 16, 2020 16:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia

– Agios Continues to Advance Two Phase 3 Combination Trials of TIBSOVO® in Newly Diagnosed AML Patients – CAMBRIDGE, Mass., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc....
September 21, 2020 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients

– Supplemental New Drug Application Planned for Submission in Q1 2021 – CAMBRIDGE, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of...
September 08, 2020 16:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs

CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...
August 27, 2020 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present at the Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020

CAMBRIDGE, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
August 06, 2020 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020

CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...
July 30, 2020 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports Business Highlights and Second Quarter 2020 Financial Results

– Second Quarter TIBSOVO® Net Revenue of $27.6 Million; Company Reiterates 2020 TIBSOVO® Net U.S. Revenue Guidance of $105–115 Million – – Significant Clinical Progress for First-in-Class PKR...
July 16, 2020 07:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Webcast Conference Call of Second Quarter 2020 Financial Results on July 30, 2020

CAMBRIDGE, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today...
June 17, 2020 16:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020

CAMBRIDGE, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced...